OmniAB Inc (OQ:OABI)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 5980 Horton Street, Suite 600
EMERYVILLE CA 94608
Tel: N/A
Website: https://www.omniab.com
IR: See website
<
Key People
John L. Higgins
Chairman of the Board
Matthew William Foehr
President, Chief Executive Officer, Director
Kurt A. Gustafson
Chief Financial Officer, Executive Vice President - Finance
Charles Stuart Berkman
Chief Legal Officer, Secretary
   
Business Overview
OmniAb, Inc. offers a discovery platform that provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable the discovery of next-generation therapeutics. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. The Company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur features structural attributes of cow antibodies for complex targets. The Company's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic target antigens.
Financial Overview
For the fiscal year ended 31 December 2023, OmniAB Inc revenues decreased 42% to $34.2M. Net loss increased from $22.3M to $50.6M. Revenues reflect License and milestone revenue segment decrease of 47% to $20.7M, Service revenue segment decrease of 35% to $12.2M. Higher net loss reflects Research and development - Balancing val increase of 15% to $43.7M (expense).
Employees: 106 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $461.26M as of Mar 31, 2024
Annual revenue (TTM): $34.16M as of Mar 31, 2024
EBITDA (TTM): -$49.92M as of Mar 31, 2024
Net annual income (TTM): -$50.62M as of Mar 31, 2024
Free cash flow (TTM): $0.70M as of Mar 31, 2024
Net Debt Last Fiscal Year: N/A
Shares outstanding: 117,145,176 as of Mar 31, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.